Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Horizon Makes The Case For An Ambitious $10Bn Sales Goal

Executive Summary

The rare disease specialist held its first R&D day since acquiring Viela Bio and laid out the development strategy for four mid-stage drugs to drive long-term growth.

You may also be interested in...



Horizon Will Submit Krystexxa sBLA To Strengthen Clinical Profile In Gout

A clinical trial confimred Krystexxa in combination with methotrexate increased response rates in patients with uncontrolled gout.

With $3bn Viela Acquisition, Horizon Builds A Pipeline

Horizon will gain the commercial product Uplizna and three pipeline products for rare diseases, where it can build on its success with Tepezza. Horizon is also interested in Viela's R&D team.

Q4 Earnings Preview: Setting The Tone For 2022 (Part 1)

Biopharma will outline its growth goals for 2022 over the coming weeks, with J&J, Novartis, AbbVie, Merck, Roche, Biogen and Lilly among the first to report.

Topics

Related Companies

UsernamePublicRestriction

Register

SC145162

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel